A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination With Mirikizumab for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis
Sponsor: Eli Lilly and Company
Listed as NCT06598943, this PHASE2 trial focuses on Ulcerative Colitis and Ulcerative Colitis Chronic and remains actively recruiting participants. Sponsored by Eli Lilly and Company, it has been updated 16 times since 2024, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
16 versions recorded-
Mar 2026 — Present [monthly]
Recruiting PHASE2
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE2
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE2
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE2
▶ Show 11 earlier versions
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE2
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE2
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE2
-
Mar 2025 — May 2025 [monthly]
Recruiting PHASE2
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE2
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE2
-
Nov 2024 — Jan 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2024 — Nov 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ankara, Turkey (Türkiye) , Athens, Greece , Augsburg, Germany , Barcelona, Spain , Baytown, United States , Belgrade, Serbia , Berlin, Germany , Bjelovar, Croatia , Bogotá, Colombia , Bologna, Italy and 161 more locations